![](https://monteverdelaw.com/wp-content/uploads/case-logo/gracell-biotechnologies-inc.jpg)
Gracell Biotechnologies Inc. (Nasdaq: GRCL), relating to its proposed sale to AstraZeneca. Under the terms of the agreement, AstraZeneca will acquire GRCL for $2.00 per share in cash (equal to $10.00 per American Depositary Share of GRCL), plus a non-tradable CVR worth $0.30 per share in cash (equal to $1.50 per ADS of GRCL) payable when regulatory milestone is achieved.